Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes
Autore:
Wimazal, F; Sperr, WR; Kundi, M; Meidlinger, P; Fonatsch, C; Jordan, JH; Thalhammer-Scherrer, R; Schwarzinger, I; Geissler, K; Lechner, K; Valent, P;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 & Hemostaseol, A-1090 Vienna, Austria Univ Vienna, Inst Environm Hyg, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Environm Hyg, A-1090 Vienna, Austria Univ Vienna, Dept Med Biol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Dept Med Biol, A-1090 Vienna, Austria Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 , Dept Lab Med, A-1090 Vienna, Austria
Titolo Testata:
LEUKEMIA RESEARCH
fascicolo: 4, volume: 25, anno: 2001,
pagine: 287 - 294
SICI:
0145-2126(200104)25:4<287:PVOLDA>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
SCORING SYSTEM; SIDEROBLASTIC ANEMIA; PROPOSALS; LEUKEMIA; SURVIVAL;
Keywords:
myelodysplastic syndromes; International Prognostic Scoring System; lactate dehydrogenase; prognostic groups; survival; AML evolution;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Valent, P Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ustria
Citazione:
F. Wimazal et al., "Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes", LEUK RES, 25(4), 2001, pp. 287-294

Abstract

Several prognostic factors for patients with myelodysplastic syndromes (MDS) have been defined in the past. One of these factors appears to be the serum lactate dehydrogenase (LDH) activity. However, the precise predictive value of an elevated LDH level with regard to AML transformation remains uncertain. In this study, the prognostic value of the LDH activity was examined in a cohort of 180 patients with de novo MDS (median age 71 years [27-93]; f/m-ratio 1:1.2; RA: n = 53; RARS: n = 37; RAEB: n = 50; RAEBT: n = 19; CMML: n = 21). Significant differences in LDH activities were found among FAB groups (P < 0.05), and especially among IPSS groups (HIGH: 411 +/- 574; INT-2: 221 +/- 90; INT-1: 254 +/- 145; LOW: 192 +/- 47 U/l; P < 0.05). An LDH level of greater than or equal to 300 U/l was found to be associated witha significantly shorter median survival (10.3 months) when compared to < 300 U/l (33.7 months; P < 0.01). Moreover, an LDH activity of greater than or equal to 300 U/l indicated a reduced AML-free survival in our MDS patients (P < 0.01). As assessed by Cox regression, the inclusion of LDH as additional variable into the IPSS system resulted in an improved prediction concerning survival, but not with regard to AML evolution. Together, our data show that a serum LDH activity of <greater than or equal to> 300 U/l in MDS is associated with a significantly shorter survival and higher risk to transform to AML. The LDH activity should be considered as an important prognostic factor in MDS. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 00:58:19